ClinicalTrials.gg
Active, not recruitingNCT05707377ALMONDUpdated Sep 11, 2026

A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy

A Phase 2/3 interventional study of Zanubrutinib and Tacrolimus in Primary Membranous Nephropathy, sponsored by BeOne Medicines. Active, not recruiting at 45 sites in 9 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-11.

Sponsored by BeOne Medicines · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
178
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 60 studies in Glomerulonephritis, Membranous with a site in China — 29 open to participants now, 37 under way, 10 of them phase 3. Glomerulonephritis, Membranous · China.

Enrollment
8th of 50
178 · median 77
Started
2023
with 7 others
Phase 2/3
4 of 60
3 open now
Primary completion
2027-10
later than 23 of 36 live
Registered
29th of 60
by date

Among the 60 studies in Glomerulonephritis, Membranous with a site in China, this one is the 8th largest by enrollment of the 50 interventional ones that give a count, is one of 8 that started in 2023, is one of 4 in phase 2/3, reaches primary completion later than 23 of the 36 other live ones, and was the 29th registered.

Glomerulonephritis, Membranous

146 studies on the registry are indexed under Glomerulonephritis, Membranous; 60 are open to participants now.

Browse Glomerulonephritis, Membranous studies →

Open to participants now

29 of the 60 studies in Glomerulonephritis, Membranous with a site in China are open now. Recruiting first, the newest first:

24 more — sign in →

All 29 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 41 Glomerulonephritis, Membranous studies recruiting now, 14 (34%) set no upper age limit and 14 (34%) stop at 75 or younger; 8 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies in Glomerulonephritis, Membranous with a site in China, or all of them as a file.
02

Study summary

The primary objectives of this study are: In Part 1 to evaluate the efficacy of zanubrutinib as measured by proteinuria reduction, and in Part 2 to evaluate the efficacy of zanubrutinib compared with tacrolimus as measured by complete remission rate, in participants with primary membranous nephropathy (PMN) who are on optimal supportive care.

Read the detailed description

Our company, previously known as BeiGene, is now officially BeOne Medicines. Because some of our older studies were sponsored under the name BeiGene, you may see both names used for this study on this website.

03

Conditions studied

  • Primary Membranous Nephropathy

Keywords

  • BGB-3111
  • Zanubrutinib
  • BTKi
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • -confirmed PMN within 5 years before the initial screening (ie, the day the is signed)
  • UPCR (based on 24-hour urine collection) > 3.5 at initial screening and at confirmation assessment
  • Treatment with a maximally tolerated or allowed dose of an angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB) for ≥ 24 weeks before randomization (12 weeks before initiation of study drug for Part 1) and with adequate blood pressure control (blood pressure \< 130/80 mmHg, measured on ≥ 2 occasions [not on the same day] within 4 weeks before the assignment of study treatment)
  • Anti-PLA2R antibody > 50 RU/mL at confirmation assessment (Part 1 only)

Exclusion criteria

Exclusion Criteria:

  • Participants with a secondary cause of membranous nephropathy
  • Type 1 or 2 diabetes mellitus with (HbA1c) ≥ 7% at screening
  • Severe renal disease as determined by rapid decline in (defined as > 15 mL/min/1.73m\^2 within 24 weeks prior to randomization, not otherwise explained)
  • A known history of a primary immunodeficiency or an underlying condition such as (HIV) infection or splenectomy that predisposes the participant to infections
  • Patients at risk for tuberculosis at screening
  • Known infection with serologic status reflecting active or chronic virus infection, or presence of virus antibody
  • Severe hepatic insufficiency ( C)
  • cardio-cerebrovascular diseases

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
178 participants (actual)

Study arms

  • Experimental
    Part 1: Zanubrutinib High Dose

    Participants will receive zanubrutinib twice daily.

    Drug: Zanubrutinib

  • Experimental
    Part 2: Zanubrutinib High Dose

    Participants will receive zanubrutinib twice daily.

    Drug: Zanubrutinib

  • Experimental
    Part 2: Zanubrutinib Low Dose

    Participants will receive zanubrutinib once daily.

    Drug: Zanubrutinib

  • Active comparator
    Part 2: Tacrolimus

    Participants will receive tacrolimus capsules twice daily for 64 weeks.

    Drug: Tacrolimus

Interventions

  • Zanubrutinib capsules administered orally.

    Also known as: BGB-3111, Brukinsa

  • Tacrolimus capsules administered orally.

06

What researchers measure

Primary outcomes

  1. Part 1: Change from Baseline in Urine Protein Creatinine Ratio (UPCR)

    Time frame: Baseline and Week 24

  2. Part 2: Number of Participants Achieving Complete Remission

    Complete remission is defined as: UPCR (based on 24-hour urine collection) ≤ 0.3, AND a stable estimated glomerular filtration rate (eGFR) (remains unchanged or decreases by \< 15% compared with the baseline)

    Time frame: Week 104

Secondary outcomes

  1. Part 1: Number of participants with Treatment Failure

    Time frame: Week 24

  2. Part 1: Number of Participants with Immunological Response

    Immunological response is defined as anti- phospholipase A2 receptor (PLA2R) antibody level reduced from baseline to less than 14 relative units (RU)/ml.

    Time frame: Week 24

  3. Part 1: Number of Participants with Complete Remission

    A complete remission is defined as: UPCR (based on 24-hour urine collection) ≤ 0.3, AND a stable eGFR (remains unchanged or decreases by \< 15% compared with the baseline)

    Time frame: Week 24, Week 52, Week 76, and Week 104

  4. Part 1: Number of Participants with Overall Remission

    Participants with overall remission are those achieving either complete remission or partial remission

    Time frame: Week 24, Week 52, Week 76, and Week 104

  5. Part 1: Number of Participants with Relapse

    A relapse is defined as reappearance of UPCR (based on 24-hour urine collection) \> 3.5 after complete or partial remission

    Time frame: Week 104

  6. Part 1: Number Of Participants with Treatment-Emergent Adverse Events (TEAEs)

    Time frame: From the first dose of study drug and up to 30 days after study drug discontinuation; up to approximately 68 weeks

  7. Part 2: Number of Participants with Overall Remission

    Participants with overall remission are those achieving either complete remission or partial remission

    Time frame: Week 24, Week 52, Week 76, and Week 104

  8. Part 2: Number of Participants with Complete Remission

    A complete remission is defined as: UPCR (based on 24-hour urine collection) ≤ 0.3, AND a stable eGFR (remains unchanged or decreases by \< 15% compared with the baseline)

    Time frame: Week 24, Week 52, and Week 76

  9. Part 2: Number of participants with Treatment Failure

    Time frame: Week 24, Week 52, Week 76, and Week 104

  10. Part 2: Time to First Complete Remission

    Time to First Complete Remission is the time from the date of randomization to the date of the first complete remission

    Time frame: Up to approximately 104 weeks

  11. Part 2: Time to First Overall Remission

    Time to first overall remission is the time from the date of randomization to the date of the first overall remission

    Time frame: Up to approximately 104 weeks

  12. Part 2: Number of Participants with Relapse

    A relapse is defined as reappearance of UPCR (based on 24-hour urine collection) \> 3.5 after complete or partial remission

    Time frame: Week 104

  13. Part 2: Time to First Relapse

    Time to first relapse is the time from the date of first complete or partial remission to the date of the first relapse

    Time frame: Up to approximately 104 weeks

  14. Part 2: Health Related quality of Life (HRQoL) Using the Kidney Disease and Quality of Life instrument™ - 36 items (KDQoL-36)

    Time frame: Up to approximately 104 weeks

  15. Part 2: Health Related quality of Life (HRQoL) Using European Quality of Life 5-Dimensions 5-Levels Health Questionnaire (EQ-5D-5L)

    Time frame: Up to approximately 104 weeks

  16. Number of Participants with ≥ 30% Estimated Glomerular Filtration Rate (eGFR) Reduction from Baseline

    Time frame: Baseline, Week 52, and Week 104

  17. Part 2: Number of Participants with TEAEs

    Time frame: From the first dose of study drug and up to 30 days after study drug discontinuation; up to approximately 68 weeks

07

Study locations

45 sites
08

References and documents

Publications

  • Ahmad SB, Jefferson JA. Targeting B Cells and Plasma Cells in Glomerular Disease. J Am Soc Nephrol. 2025 Jun 4;36(9):1844-1857. doi: 10.1681/ASN.0000000772. PubMed 40465397 ↗

Individual participant data

Plan to share: Yes — BeOne shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved. BeOne shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations. Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeOne review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See plan description

Access criteria: See plan description

Data sharing details ↗ · beonemedicines.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2023 (actual). Primary completion is estimated for Oct 2027, 54 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2023
First posted
Jan 31, 2023
StartActual
Apr 17, 2023
Primary completionEst.
Oct 2027
CompletionEst.
Oct 2027
Last update
Sep 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05707377
Lead sponsor
BeOne Medicines
Responsible party
Sponsor
First posted
Jan 31, 2023
Start date
Apr 17, 2023
Primary completion
Oct 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Sep 11, 2026

Study contacts

Study Director
study director · BeOne Medicines

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zanubrutinib

Start the discussion